1. Home
  2. APLE vs IMNM Comparison

APLE vs IMNM Comparison

Compare APLE & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Apple Hospitality REIT Inc.

APLE

Apple Hospitality REIT Inc.

HOLD

Current Price

$15.95

Market Cap

2.9B

Sector

Real Estate

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$18.51

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APLE
IMNM
Founded
2007
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.6B
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
APLE
IMNM
Price
$15.95
$18.51
Analyst Decision
Buy
Strong Buy
Analyst Count
8
10
Target Price
$13.00
$32.80
AVG Volume (30 Days)
2.3M
1.1M
Earning Date
05-04-2026
05-08-2026
Dividend Yield
7.12%
N/A
EPS Growth
N/A
51.40
EPS
0.12
N/A
Revenue
$1,238,622,000.00
$6,941,000.00
Revenue This Year
$2.31
N/A
Revenue Next Year
$2.35
$1,127.34
P/E Ratio
$129.96
N/A
Revenue Growth
18.98
N/A
52 Week Low
$10.85
$7.96
52 Week High
$15.81
$27.65

Technical Indicators

Market Signals
Indicator
APLE
IMNM
Relative Strength Index (RSI) 77.51 34.39
Support Level $11.50 $16.81
Resistance Level N/A $19.16
Average True Range (ATR) 0.33 1.23
MACD 0.07 -0.32
Stochastic Oscillator 96.78 8.72

Price Performance

Historical Comparison
APLE
IMNM

About APLE Apple Hospitality REIT Inc.

Apple Hospitality REIT Inc is a real estate investment trust that invests in income-producing real estate, majorly in the lodging sector, in the United States. It chiefly invests in upscale service hotels. All of the company's hotels operate under the Marriott or Hilton brands. Apple Hospitality has wholly-owned taxable REIT subsidiaries, which lease all of the company's hotels from wholly-owned qualified REIT subsidiaries. These hotels are managed under separate agreements with various hotel management companies that are unaffiliated with Apple Hospitality. The company derives its income from hotel revenue, its sole segment.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: